STC2 (Stanniocalcin 2)
A secreted glycoprotein involved in calcium/phosphate homeostasis, hypoxia response, and tumorigenesis
Gene Information Card
| Symbol | STC2 |
|---|---|
| Full Name | Stanniocalcin 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 5q35.2 |
| NCBI Gene ID | 8614 ncbi.nlm.nih.gov/gene/8614 |
| Ensembl ID | ENSG00000113739 |
| UniProt ID | O76061 |
| OMIM ID | 603665 |
| HGNC ID | 11373 |
| Aliases | STC-2, stanniocalcin-2 |
Description
STC2 encodes stanniocalcin 2, a secreted homodimeric glycoprotein that regulates calcium and phosphate homeostasis. It is induced by hypoxia via HIF-1α and modulates cell proliferation, migration, and survival. STC2 is overexpressed in multiple cancers and is associated with poor prognosis.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | STC2 overexpression promotes tumor growth and metastasis via PI3K/AKT signaling | PMID: 25642768 |
| Colorectal cancer | Elevated STC2 correlates with advanced stage and poor survival | PMID: 27840973 |
| Ovarian cancer | STC2 enhances chemoresistance through ERK pathway activation | PMID: 29351287 |
| Hypoxia-related disorders | STC2 is a direct HIF-1 target, upregulated under low oxygen | PMID: 15297311 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Kidney | 12.5 | Medium |
| Liver | 8.3 | Low |
| Heart | 6.1 | Low |
| Brain | 4.2 | Low |
| Placenta | 15.7 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 (breast cancer) | 18.2 | High expression |
| HCT116 (colorectal) | 22.1 | High expression |
| HEK293 (embryonic kidney) | 9.8 | Moderate expression |
| A549 (lung cancer) | 14.5 | High expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.331C>T (p.Arg111Cys) | Missense | <0.1% | Unknown functional impact |
| c.487G>A (p.Gly163Ser) | Missense | <0.1% | Reported in COSMIC |
| c.614_615insA | Frameshift | <0.1% | Predicted loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift insertions (e.g., c.614_615insA) likely produce truncated, non-functional protein.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported in STC2.
Dominant Negative (DN)
No evidence of dominant-negative effects for STC2 mutations.
View complete mutation data：
Gene Ontology (GO)
Pathways
• HIF-1 signaling pathway (Reactome: R-HSA-1234174)
• Calcium signaling pathway (KEGG: hsa04020)
• PI3K-Akt signaling pathway (KEGG: hsa04151)
Protein Summary
Stanniocalcin 2 is a 302-amino-acid secreted glycoprotein that forms homodimers. It contains a conserved stanniocalcin domain and is involved in calcium/phosphate regulation. The protein is induced by hypoxia and can activate MAPK/ERK and PI3K/AKT signaling. It is implicated in cancer progression, chemoresistance, and metabolic disorders.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| STC2 Knockout HEK293 Cell Line | EDJ-KQ3623 | Human | 8614 | Details Get a Quote |
| STC2 Knockout HeLa Cell Line | EDJ-KQ24188 | Human | 8614 | Details Get a Quote |
| STC2 Knockout A-549 Cell Line | EDJ-KQ25562 | Human | 8614 | Details Get a Quote |
| STC2 Knockout HCT 116 Cell Line | EDJ-KQ25563 | Human | 8614 | Details Get a Quote |
